Healthcare


 Fonterra Gears Up for Potential IPO with Key Leadership Appointment

Fonterra Gears Up for Potential IPO with Key Leadership Appointment

April 17, 2025 04:28 PM AEST| By Team Kalkine Media

Highlights,Anne Templeman-Jones joins board of Fonterra’s consumer unit,Strategic move fuels IPO and trade sale possibilities,Consumer arm estimated at up to $4 billion,Fonterra Co-operative Group (ASX:FCG), one of the world’s largest dairy exporters...

 Clarity Pharmaceuticals Jumps on Breakthrough US Production Deal for Cancer Imaging Isotope

Clarity Pharmaceuticals Jumps on Breakthrough US Production Deal for Cancer Imaging Isotope

April 17, 2025 04:04 PM AEST| By Team Kalkine Media

Highlights,Clarity inks commercial production deal for copper-64 with Nusano,Shares rise over 12%, topping ASX 200 leaderboard,$11.1M tax incentive to boost product development,Clarity Pharmaceuticals (ASX:CU6) saw a notable surge in its share price...

 Lumos Diagnostics Advances FebriDx® Rollout with Medicare Approval Supporting ASX Healthcare Stocks Momentum

Lumos Diagnostics Advances FebriDx® Rollout with Medicare Approval Supporting ASX Healthcare Stocks Momentum

April 17, 2025 02:33 PM AEST| By Team Kalkine Media

Highlights:,Lumos Diagnostics secures reimbursement for FebriDx® through key US Medicare contractors.,FebriDx® test added to national reimbursement schedule, expanding access across clinical settings.,Broader Medicare engagement may strengthen outloo...

 InhaleRX initiates Phase 1 trial for inhaler designed to treat panic disorder.

InhaleRX initiates Phase 1 trial for inhaler designed to treat panic disorder.

April 17, 2025 01:30 PM AEST| By Team Kalkine Media

Highlights,InhaleRX initiates clinical trials for its cannabidiol-based inhaler therapy, IRX-616a.,Study conducted in Adelaide under the supervision of iNGENū CRO Pty Ltd.,Clendon Biotech Capital provides multi-million dollar funding to support clini...

 Lumos Diagnostics Wins Key US Medicare Support for FebriDx®, Eyes Wider Market Reach

Lumos Diagnostics Wins Key US Medicare Support for FebriDx®, Eyes Wider Market Reach

April 17, 2025 01:00 PM AEST| By Team Kalkine Media

Highlights,Medicare reimbursement secured for,FebriDx,® in major regions,$41.38 per test rate set to begin from April 2025,Broader US market access expected as discussions advance,Lumos Diagnostics Holdings Ltd (ASX:LDX) has taken a major step forwar...

 Dissecting the Shareholder Dynamics of Sonic Healthcare Limited (ASX:SHL)

Dissecting the Shareholder Dynamics of Sonic Healthcare Limited (ASX:SHL)

April 17, 2025 12:34 PM AEST| By Team Kalkine Media

Highlights,Individual investors hold significant influence in Sonic Healthcare Limited (SHL).,Institutions account for a substantial 40% ownership.,Insider ownership is notable with a stake worth AU$137 million.,Understanding the distribution of owne...

 Is the Recent Stock Performance of Austco Healthcare Limited (ASX:AHC) Linked to Its Robust Fundamentals?

Is the Recent Stock Performance of Austco Healthcare Limited (ASX:AHC) Linked to Its Robust Fundamentals?

April 17, 2025 12:32 PM AEST| By Team Kalkine Media

Highlights:,Austco Healthcare (ASX:AHC) displays strong financial indicators with a rising return on equity.,Earnings growth remains solid, exceeding broader industry benchmarks over the long term.,Strategic reinvestment of earnings supports operatio...

 COH Share Price and JBH Performance: Developments in ASX Healthcare Stocks and Retail Sector

COH Share Price and JBH Performance: Developments in ASX Healthcare Stocks and Retail Sector

April 16, 2025 05:05 PM AEST| By Team Kalkine Media

Highlights:,COH share price has declined since the start of the year, drawing attention to its recent financial outcomes.,JBH revenue and net profit movements reflect broader trends in consumer electronics retailing.,Focus on,ASX Healthcare Stocks,su...

"Growth" Defines Firebrick's (ASX:FRE) Sales-Focused Quarter

April 16, 2025 03:30 PM AEST| By Team Kalkine Media

Highlights:,Firebrick Pharma expands its Nasodine product line across multiple global markets, including Singapore, the United States, and the South Pacific.,Key collaborations with local partners, such as Innorini Life Sciences and Makans, support t...

 PainChek (ASX:PCK) Strengthens Growth Prospects with R&D Boost, FDA Progress, and Infant App Launch

PainChek (ASX:PCK) Strengthens Growth Prospects with R&D Boost, FDA Progress, and Infant App Launch

April 16, 2025 03:16 PM AEST| By Team Kalkine Media

Highlights,$1.41M R&D tax refund extends financial runway,US FDA review of Adult App progressing steadily,Infant App launches with strong early reception,PainChek (ASX:PCK),is making notable strides in its mission to transform pain assessment through...

 The Share Price of Althea Group Holdings Limited (ASX:AGH) Reflects Market Sentiment Regarding Its Revenues

The Share Price of Althea Group Holdings Limited (ASX:AGH) Reflects Market Sentiment Regarding Its Revenues

April 16, 2025 02:33 PM AEST| By Team Kalkine Media

Highlights:,Althea Group Holdings exhibits a low price-to-sales ratio, reflecting its below-industry valuation.,The company has shown positive revenue growth, though it trails behind industry growth projections.,Investor sentiment indicates cautious...

 Why Healthcare Tech is on the Radar: A Closer Look at Pro Medicus (ASX:PME)

Why Healthcare Tech is on the Radar: A Closer Look at Pro Medicus (ASX:PME)

April 16, 2025 02:10 PM AEST| By Team Kalkine Media

Highlights,PME delivers radiology tech that supports faster diagnostics,Healthcare sector offers stable revenue and long-term growth,PME trades at a premium valuation with rising revenue,Pro Medicus (ASX:PME), a leading healthcare technology provider...

 PTX-100 Moves Closer to Market as FDA Grants Fast-Track Status to Prescient Therapeutics

PTX-100 Moves Closer to Market as FDA Grants Fast-Track Status to Prescient Therapeutics

April 16, 2025 01:46 PM AEST| By Team Kalkine Media

Highlights,PTX-100 receives fast-track status from FDA,Promising early results in treating T-cell lymphoma,Phase 2 trials underway across multiple regions,Prescient Therapeutics (ASX:PTX) has achieved a key regulatory milestone, with its lead drug ca...

 NeuroScientific (ASX:NSB) Accelerates Stem Cell Advancements with Strategic Acquisition of Isopogen

NeuroScientific (ASX:NSB) Accelerates Stem Cell Advancements with Strategic Acquisition of Isopogen

April 16, 2025 01:32 PM AEST| By Team Kalkine Media

Highlights,NeuroScientific acquires Isopogen and its patented StemSmart technology,Focus on regenerative stem cell therapies for neurodegenerative disorders,New clinical trials planned to drive regulatory path forward,NeuroScientific Biopharmaceutica...

 Tryptamine Therapeutics (ASX:TRP) Launches Groundbreaking Psilocybin Trial for Binge Eating Disorder

Tryptamine Therapeutics (ASX:TRP) Launches Groundbreaking Psilocybin Trial for Binge Eating Disorder

April 16, 2025 01:14 PM AEST| By Team Kalkine Media

Highlights,New trial with Swinburne University targets binge eating disorder,TRP-8803 infusion aims to assess impact on eating behavior, mental health,Builds on strong Phase 2 results from prior psilocybin studies,Tryptamine Therapeutics (ASX:TRP) ha...

 FDA Fast Track Boosts Prescient’s PTX-100 Toward Commercialisation Milestone

FDA Fast Track Boosts Prescient’s PTX-100 Toward Commercialisation Milestone

April 16, 2025 11:11 AM AEST| By Team Kalkine Media

Highlights,PTX-100 granted Fast Track status by US FDA,Clinical-stage progress enhances commercial pathway,Phase 2 trial in CTCL advancing toward patient enrolment,Prescient Therapeutics (ASX:PTX) has taken a significant step forward in its oncology...

 Shareholders Should Not Ignore Pro Medicus Insiders Selling AU$514 Million in Stock

Shareholders Should Not Ignore Pro Medicus Insiders Selling AU$514 Million in Stock

April 15, 2025 10:30 PM AEST| By Team Kalkine Media

Highlights,Pro Medicus Limited (PME) experienced a notable stock price increase of 20% last week.,Insider transactions have favored sales over purchases in the past year, raising interest and curiosity.,Insider ownership stands at 49%, promoting alig...

 Navigating Volatile Markets with Quality ASX Healthcare Stocks and ETFs

Navigating Volatile Markets with Quality ASX Healthcare Stocks and ETFs

April 15, 2025 03:40 PM AEST| By Team Kalkine Media

Highlights,Focus remains on established ASX 200 companies with strong fundamentals and resilient business models,Select ASX ETFs offer diversified exposure to global and local leaders across multiple sectors,Dividend-paying shares in consumer staples...

 Clarity Pharmaceuticals and Key Developments in ASX Penny Stocks – April 2025

Clarity Pharmaceuticals and Key Developments in ASX Penny Stocks – April 2025

April 15, 2025 02:44 PM AEST| By Team Kalkine Media

Highlights,Clarity Pharmaceuticals progresses in radiopharmaceutical research with a focus on prostate cancer,Deep Yellow advances uranium exploration efforts in Namibia and Australia,Stanmore Resources experiences fluctuations in revenue and earning...

 Pro Medicus signs R&D agreement with UCSF for Visage AI Accelerator

Pro Medicus signs R&D agreement with UCSF for Visage AI Accelerator

April 15, 2025 02:30 PM AEST| By Team Kalkine Media

Highlights:,Pro Medicus partners with University of California San Francisco to advance AI in medical imaging.,The collaboration aims to enhance the Visage AI Accelerator platform's capabilities.,The partnership emphasizes the integration of clinical...

AU_advertise

Advertise your brand on Kalkine Media

Recent Articles






Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.